Skip to main content

Table 2 Anthropometric, vital, and laboratory data at baseline and 1-year follow-up

From: Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study

Parameter

Baseline

1-year follow-up

Change

P-value 1)

 

n

mean ± SD

n

mean ± SD

n

mean ± SD

 

Body weight, kg

491

62.2 ± 12.4

434

63.5 ± 11.8

434

1.3 ± 4.3

***

BMI, kg/m2

490

23.9 ± 4.0

433

24.4 ± 3.7

433

0.5 ± 1.6

***

HbA1c, %

506

10.3 ± 2.0

482

7.5 ± 1.3

478

−2.7 ± 2.2

***

FPG, mg/dL

254

217.3 ± 80.8

137

139.0 ± 48.7

91

−79.0 ± 92.9

***

PPG, mg/dL

329

296.1 ± 96.0

380

178.2 ± 68.6

256

−115.9 ± 111.1

***

Total cholesterol, mg/dL

439

201.4 ± 43.6

309

187.7 ± 35.9

286

−12.6 ± 44.2

***

LDL-cholesterol, mg/dL

294

122.0 ± 34.0

383

110.5 ± 28.3

239

−11.0 ± 32.0

***

HDL-cholesterol, mg/dL

       

Men

277

50.0 ± 13.7

268

53.2 ± 15.2

234

3.1 ± 11.3

***

Women

163

56.8 ± 15.9

151

58.1 ± 15.7

135

2.3 ± 12.1

*

Triglycerides, mg/dL

465

159.7 ± 132.0

447

138.0 ± 85.3

410

−19.7 ± 128.3

**

Creatinine, mg/dL

404

0.76 ± 0.42

422

0.86 ± 0.58

334

0.11 ± 0.66

**

SBP, mmHg

474

132.1 ± 18.5

466

132.8 ± 17.7

435

1.0 ± 20.6

N.S.

DBP, mmHg

474

76.5 ± 11.7

466

74.5 ± 10.8

435

−1.9 ± 12.4

**

  1. Abbreviations: BMI body mass index, DBP diastolic blood pressure, FPG fasting plasma glucose, Hb hemoglobin, HDL high-density lipoprotein, LDL low-density lipoprotein, PPG postprandial plasma glucose, SBP systolic blood pressure.
  2. 1)Paired t-test.
  3. N.S. not statistically significant, *P < .05, **P < .01, ***P < .001.